Author

Kelly A. Correll

National Jewish Health

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Anna BackmarkiD· 1 shared Benjamin P. Readhead· 1 shared Björn Magnusson· 1 shared Carly MeadoriD· 1 shared Christine BeckeriD· 1 shared Daniel G. FosteriD· 1 shared Farida AhangariiD· 1 shared Giuseppe Deluliis· 1 shared

Activity by Year

2022-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperSystems Biology

Anna BackmarkORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in In Vitro, In Vivo and Ex Vivo Models of Pulmonary Fibrosis

Farida Ahangari, Christine Becker, Daniel G. Foster, Maurizio Chioccioli, Meghan Nelson, K.M. Beke, Xing Wang, Benjamin P. Readhead, Carly Meador, Kelly A. Correll, Loukia N. Lili, Helen M. Roybal, Kadi-Ann Rose, Shuizi Ding, Thomas Bärnthaler, , Gregory Paul Downey

This study identifies saracatinib as a potential anti-fibrotic drug effective in multiple models of pulmonary fibrosis, showing equal or superior efficacy compared to existing treatments.

bioRxiv · Jan 4, 2022 · PreprintSystems Biology